AlphAIalphai — Financial news for AI agents
investing.comAUG 53 min read$LIVN

Why is LivaNova stock climbing today?

LivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.

Original reporting
investing.com
Published Aug 5, 2026, 10:24 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$LIVN
Bullish
high confidence
Mentioned
$LIVN
Relevance
9/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$LIVNBullishHigh
01

Why it matters

Guidance lift and product momentum can change forward earnings expectations, supporting higher valuation multiples if investors believe the trend is sustainable.

02

Market read

A same-day earnings beat plus a second consecutive annual guidance raise is a high-signal catalyst that can drive continued momentum into the next trading session.

03

What to watch

The article does not discuss margins, cash flow, or competitive dynamics; traders may need to verify whether the beat is quality earnings or one-off strength.

Relevance 9/10Novelty 9/10Timing: after-hours today, following Q2 2026 results and same-day guidance raise

Background

The piece frames LivaNova’s after-hours rise as driven by Q2 2026 results and an upgraded full-year EPS outlook, with aura6000 cited as a growth driver.

Company-level read

Ticker impact

$LIVNBullishHigh confidence
Context

LivaNova reported Q2 2026 results that beat EPS and revenue estimates and raised full-year adjusted diluted EPS guidance to $4.30 to $4.40.

Expected impact

Bullish bias for the next session(s) as traders reprice durability of cardiopulmonary and aura6000 growth.

Evidence & confidence

The article cites specific Q2 outperformance and an explicit full-year guidance upgrade with a raised analyst price target, which typically drives immediate repricing.

Market effects

Sector

Positive read-through for medical technology and sleep apnea device demand expectations, especially for neuromodulation platforms.

Regional

No specific regional catalyst beyond US market being broadly neutral.

Global

Limited global spillover; story is company-specific with FDA-approved product momentum.

Counterpoint

What could challenge this read

The move may fade if investors over-extrapolate aura6000 commercial ramp beyond what the raised guidance range implies.

Key entities

  • company
    LivaNova

    Medical technology company whose Q2 results and raised 2026 EPS guidance drove the stock’s after-hours climb.

  • product
    aura6000

    FDA-approved hypoglossal nerve stimulation device for obstructive sleep apnea, cited as a growing commercial opportunity.

  • analyst_firm
    KeyBanc

    Maintained Overweight rating and raised its price target to $92 from $83.

Read at source← All news

Related articles

AUG 7
$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

yahoo.com7 min
AUG 5
$LIVNHighAI 9/10

LivaNova Q2 Earnings Call Highlights

LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.

yahoo.com6 min
AUG 5
$LIVNHighAI 9/10

LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.

finanznachrichten.de7 min
AUG 5
$LIVNHigh

LivaNova PLC (LIVN): Results of Operations and Financial Condition

LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q2026earningspressrelease.htm EX-99.1 Document EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency rev

SEC EDGAR 8-K6 min
AUG 9
$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

peakoil.com4 min
AUG 9
$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

yahoo.com6 min